Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 23

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 23
---
350,000 and borrowings
from its founders in the total aggregate amount of $1,075,000. In addition, while DiamiR has not earned revenue from its planned primary
operations, DiamiR has received fees for performing specified clinical and other testing services from commercial entities from time
to time. DiamiR has not, however, received such fees since March 2022. The amount of DiamiR’s future net losses will depend,
in part, on the rate of future growth of its expenses and DiamiR’s ability to generate revenues. If DiamiR is unable to develop
and commercialize CogniMIR or any other product candidates that it may seek to develop, either alone or with collaborators,
or if revenues from any product candidate that receives marketing approval are insufficient, DiamiR will not achieve profitability. Even
if DiamiR does achieve profitability, DiamiR may not be able to sustain or increase profitability.

Since inception, DiamiR has
raised over $9.7 million in grant funding from government agencies and disease foundations. On October 1, 2020, DiamiR announced
that it received two grants from the National Institutes of Health (NIH) in the total amount of approximately $3.86 million. The
National Institute on Aging (NIA) awarded DiamiR approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as
part of its Small Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration
with leading academic centers and continues to support development of CogniMIR, DiamiR’s lead diagnostic product
candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR
by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs
as biomarkers of Rett Syndrome.”

From June 2020 through April
2023, Kira Sheinerman, one of the founders and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which
role included reviewing therapeutic and diagnostic opportunities, and making industry and academia introductions for Aptorum. Kira Sheinerman
currently hold 2,772 shares of Aptorum.

Company management believes
that by merging these two companies together, it can achieve greater shareholder value and have a